Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study
Circulation · 2023
DOI: 10.1161/circulationaha.122.062123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2023. Verfasst von Eric A Secemsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (E…. Hauptthemen laut MEDLINE: Blood Vessel Prosthesis Implantation, Endovascular Procedures, Aortic Aneurysm, Abdominal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Concerns have been raised about the long-term performance of aortic stent grafts for the treatment of abdominal aortic aneurysms, in particular, unibody stent grafts (eg, Endologix AFX AAA stent grafts). Only limited data sets are available to evaluate the long-term risks related to these devices. The SAFE-AAA Study (Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries Study) was designed with the Food and Drug Administration to provide a longitudinal assessment of the safety of unibody aortic stent grafts among Medicare beneficiaries.
Methods
The SAFE-AAA Study was a prespecified, retrospective cohort study evaluating whether unibody aortic stent grafts are noninferior to non-unibody aortic stent grafts with respect to the composite primary outcome of aortic reintervention, rupture, and mortality. Procedures were evaluated from August 1, 2011, through December 31, 2017. The primary end point was evaluated through December 31, 2019. Inverse probability weighting was used to account for imbalances in observed characteristics. Sensitivity analyses were used to evaluate the effect of unmeasured confounding, including assessment of the falsification end points heart failure, stroke, and pneumonia. A prespecified subgroup included patients treated from February 22, 2016, through December 31, 2017, corresponding to the market release of the most contemporary unibody aortic stent grafts (Endologix AFX2 AAA stent graft).
Results
Of 87 163 patients who underwent aortic stent grafting at 2146 US hospitals, 11 903 (13.7%) received a unibody device. The average age of the total cohort was 77.0±6.7 years, 21.1% were female, 93.5% were White, 90.8% had hypertension, and 35.8% used tobacco. The primary end point occurred in 73.4% of unibody device-treated patients versus 65.0% of non-unibody device–treated patients (hazard ratio, 1.19 [95% CI, 1.15–1.22]; noninferior P value of 1.00; median follow-up, 3.4 years). Falsification end points were negligibly different between groups. In the subgroup treated with contemporary unibody aortic stent grafts, the cumulative incidence of the primary end point occurred in 37.5% of unibody device–treated patients and 32.7% of non-unibody device–treated patients (hazard ratio, 1.06 [95% CI, 0.98–1.14]).
Conclusions
In the SAFE-AAA Study, unibody aortic stent grafts failed to meet noninferiority compared with non-unibody aortic stent grafts with respect to aortic reintervention, rupture, and mortality. These data support the urgency of instituting a prospective longitudinal surveillance program for monitoring safety events related to aortic stent grafts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (E.A.S., Y.S., T.S., J.X., R.W.Y.).
- Harvard Medical School, Boston, MA (E.A.S., R.W.Y.).
- Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (E.A.S., R.W.Y.).
- Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (C.G.J., M.G., L.W., A.F., R.E.L., A.S.).
ORCID-Profile: Eric A Secemsky, Tianyu Sun, Robert E Lee, Robert W Yeh
Förderung
- NHLBI NIH HHS
Zitieren
APA
Secemsky, E. A., Song, Y., Sun, T., Johnson, C. G., Gatski, M., Wang, L., Farb, A., Lee, R. E., Shaw, A., Xu, J., & Yeh, R. W. (2023). Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study. Circulation. https://doi.org/10.1161/circulationaha.122.062123
Vancouver
Secemsky EA, Song Y, Sun T, Johnson CG, Gatski M, Wang L, et al. Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study. Circulation. 2023. doi:10.1161/circulationaha.122.062123
BibTeX
@article{Secemsky2023,
author = {Secemsky, Eric A and Song, Yang and Sun, Tianyu and Johnson, Carmen Gacchina and Gatski, Megan and Wang, Li and Farb, Andrew and Lee, Robert E and Shaw, Aurko and Xu, Jiaman and Yeh, Robert W},
title = {Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.122.062123}
}
EUVIMED